EICHORPublic-registry site landscape for NCT07709897, “A Clinical Trial of HRS5580 for Injection Combined With Palonosetron Hydrochloride for the Prevention of Postoperative Nausea and Vomiting”, a Prevention of Postoperative Nausea and Vomiting study sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07709897 (registry record) |
| Study title | A Clinical Trial of HRS5580 for Injection Combined With Palonosetron Hydrochloride for the Prevention of Postoperative Nausea and Vomiting |
| Official title | A Multicenter, Randomized, Dose-finding, Positive-controlled, Double-blind, Double-dummy Phase II Clinical Trial to Evaluate the Efficacy and Safety of HRS5580 for Injection Combined With Palonosetron Hydrochloride in the Prevention of Postoperative Nausea and Vomiting |
| Sponsor | Fujian Shengdi Pharmaceutical Co., Ltd. |
| Condition(s) | Prevention of Postoperative Nausea and Vomiting |
| Phase | PHASE2 |
| Listed sites | 2 |
| Site countries | China |
Patient-friendly overview of this study: eichor.com/study/NCT07709897.
Eichor generates a preliminary site-risk snapshot for NCT07709897 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
More from Fujian Shengdi Pharmaceutical Co., Ltd.
← Eichor home · All tracked trials · Prevention of Postoperative Nausea and Vomiting studies · Weekly briefs
